Veeva Systems (NYSE: VEEV) today announced that Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has committed to Veeva Vault CRM.

Merck (MRK) recently announced a dividend of $0.81 per share for Q4 2025 and gained Health Canada approval for KEYTRUDA® in treating cervical cancer. These developments align with Merck’s ...

Key Points Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a treatment for COPD -- to its portfolio.

A change in full-year guidance by management wasn't particularly welcome.

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by the end of 2027.

Merck posted lower Q2 earnings as vaccine sales dropped, but oncology and animal health segments saw strong growth; 2025 guidance slightly raised.

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a trial last year, the firm’s cancer drug outperformed the world’s ...

Merck Unveils New Facility to Increase Vaccine Production CapacityDURHAM, N.C.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the ...

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst ...

Merck & Co., Inc. (NYSE: MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person’s hand holding a bottle of pharmaceuticals.